Construction of the facility in Laval, Quebec, is a milestone for both Moderna and Canada, as the country progresses towards delivering a domestic mRNA vaccine supply chain.
KEY INFORMATION
Location: Quebec, Canada
Date started: 2023
Completion date: 2024
Client type: real estate
Main capabilities: cost and commercial management, project management
Building resilience against future pandemics
Moderna is a pharmaceutical company with a mission to deliver the greatest possible impact to people through mRNA, including one of the earliest and most effective COVID-19 vaccines. Moderna’s first mRNA facility in Canada will build local resilience for future pandemic responses and the facility is expected to be operational in 2025, with a capacity of 100m doses per year.
Driving an integrated project schedule
In March 2023 we were appointed to provide project management, schedule management, risk, and cost and commercial management capabilities for construction on the facility, with our contract later including the completion of the CQV (commissioning, qualification and verification).
Key to our involvement was the creation of a project execution plan, including an integrated project schedule, effective implementation of project controls, and the streamlining of decision-making and approval processes. Our ability to build strong relationships between construction management and principal designer, creating a ‘one-team’ mindset, was a key factor in delivering the project.
Following the successful completion of our work on the Laval project, we have since been appointed by Moderna to several additional global projects, including the Genomics Lab Expansion at Moderna’s headquarters in Massachusetts, as well as to provide project management support on real estate projects globally.
A developing partnership
Underscoring Moderna’s commitment to sustainability and achieving decarbonisation goals, the design of the facility aims to significantly reduce fossil-fuel usage. Moderna has targeted achieving net-zero emissions in scopes 1 and 2 by 2030.
As well as prioritising sustainability, Moderna’s work aims to strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.
